Board of Directors

William B. Stilley, MBA
Chair

William Stilley has over two decades of experience as a life science entrepreneur and executive. Before founding Adovate, he served as CEO of Adial Pharmaceuticals, which he founded and took public.

Other notable roles include VP, Business Development & Strategic Projects at Clinical Data, Inc. (acquired by Forest Laboratories), Chief Business Officer at Diffusion Pharmaceuticals (Nasdaq: DFSN), and COO/CFO at Adenosine Therapeutics. Mr. Stilley has been engaged in all aspects of drug discovery and development including licensing and M&A transactions, management of clinical trials, and production of and manufacturing for multiple drug candidates. He has been a Guest Lecturer at the UVA’s Darden School of Business and serves as an Advisory Board Member for Virginia BIO, as well as Director of Adial Pharmaceuticals, Inc. (Nasdaq) and Avalon GloboCare Corp. He received an MBA with honors from UVA’s Darden School of Business, and a Bachelor of Science in Marketing from the UVA McIntire School of Commerce.
Read More
Robert S. Capon, MBA
Vice Chair

Experienced life science entrepreneur and executive. CEO and Co-founder Adenosine Therapeutics until it was sold. Advisor and Board member for numerous companies over the years.

Mr. Capon earned his MBA from the Harvard Business School, and a Bachelor in Science for Mechanical Engineering at the University of Virginia.
Read More
Andrew J. Stevens, PhD

Experienced executive and board member. Currently Manager for Second Miler, LLC, a private equity investment firm. Previously, Managing Director and co-founder of DC Energy; co-founder Nodal Exchange, LLC; Manager & VP of Dean & Company.

Additional experience includes strategy consulting with a focus on energy and telecommunications. Dr. Stevens received a Ph.D. degree in Chemical Physics from Harvard University, and a Bachelor of Science in Chemistry from the California Institute of Technology.
Read More
Joseph A. M. Truluck, MBA

Experienced life strategy and finance executive. Currently Chief Finance Officer of Adial Pharmaceuticals (Nasdaq ADIL). Formerly, with Clinical Data, Inc. (Nasdaq: CLDA), Forest Laboratories, and Adenosine Therapeutics. 

Mr. Truluck received his MBA from Tulane University School of Business, an MA in Philosophy from the University of Virginia, and a BA in Political Science and Philosophy from Florida State University. 
Read More